Topiramate (Epilepsy)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12871
R48604
Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Cardiac malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.90 [0.07;50.68] C
excluded (control group)
0/9   1/50 1 9
ref
S12872
R48614
Thomas (Topiramate) (Controls unexposed, sick), 2021 Cardiac malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 2.05 [0.11;38.10] C 0/9   9/340 9 9
ref
S7662
R22677
Tomson (Topiramate), 2018 Cardiac malformations at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 3.35 [0.96;11.71] C 3/152   15/2,514 18 152
ref
S9837
R37712
Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Cardiac Malformations at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.02 [0.05;20.14] C
excluded (control group)
0/44   3/315 3 44
ref
S9838
R37716
Vajda (Topiramate) (Controls unexposed, sick), 2013 Cardiac Malformations at least 1st trimester prospective cohort unexposed, sick Adjustment: No 1.11 [0.04;27.86] C 0/44   1/147 1 44
ref
S6061
R15760
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Cardiac 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.60 [0.14;49.43] C 0/28   4/647 4 28
ref
Total 4 studies 2.75 [0.99;7.59] 32 233
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Topiramate) (Controls unexposed, sick), 2021Thomas, 2021 1 2.05[0.11; 38.10]9912%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Tomson (Topiramate), 2018Tomson, 2018 2 3.35[0.96; 11.71]1815266%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Vajda (Topiramate) (Controls unexposed, sick), 2013Vajda, 2013 3 1.11[0.04; 27.86]14410%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 4 2.60[0.14; 49.43]42812%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 2.75[0.99; 7.59]322330.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, sick; 2: Topiramate; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.75[0.99; 7.59]322330%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 4 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.56[0.18; 13.54]10530%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Vajda (Topiramate) (Controls unexposed, sick), 2013 2 exposed to other treatment, sickexposed to other treatment, sick 3.23[1.02; 10.20]221800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 2.75[0.99; 7.59]322330%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 4 All studiesAll studies 2.75[0.99; 7.59]322330%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.94.91.9710.000Thomas (Topiramate) (Controls unexposed, sick), 2021Tomson (Topiramate), 2018Vajda (Topiramate) (Controls unexposed, sick), 2013Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9837, 12871

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.56[0.18; 13.54]10530%NAThomas (Topiramate) (Controls unexposed, sick), 2021 Vajda (Topiramate) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.68[0.97; 7.43]262330%NAThomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0